Abigirl Machingura

Avenue Emmanuel Mounier 83/11
Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

What's missing in patient-reported outcome reporting? A scoping review and aggregated trial-level analysis of completion rates in oncology randomized controlled trials.

What's missing in patient-reported outcome reporting? A scoping review and aggregated trial-level analysis of completion rates in oncology randomized controlled trials.

Journal: Critical reviews in oncology/hematology

Published: September 15, 2025

Assessing the assessment: a scoping review of the mode of patient-reported outcome assessment in solid cancer clinical trials.

Assessing the assessment: a scoping review of the mode of patient-reported outcome assessment in solid cancer clinical trials.

Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Published: August 19, 2025

SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials.

SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials.

Journal: The Lancet. Oncology

Published: March 30, 2025

Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study.

Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study.

Journal: Neuro-oncology practice

Published: March 20, 2025

Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study.

Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study.

Journal: EClinicalMedicine

Published: October 09, 2024

Improving completion rates of patient-reported outcome measures in cancer clinical trials: Scoping review investigating the implications for trial designs.

Improving completion rates of patient-reported outcome measures in cancer clinical trials: Scoping review investigating the implications for trial designs.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 26, 2024

Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort.

Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort.

Journal: Clinical and translational radiation oncology

Published: October 03, 2023

Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091).

Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091).

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 11, 2023

Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study.

Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 01, 2022

Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit.

Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit.

Journal: Journal of the National Cancer Institute

Published: August 29, 2018

Showing 1-10 of 10

Last Updated: 09/26/2026